Eli Lilly oral GLP-1 linked to lower predicted diabetes, CV risk
Lilly said its oral GLP-1, orforglipron, was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.